Nicotinamide Mononucleotide (NMN): Difference between revisions

Nicotinamide Mononucleotide (NMN) (view source)

398 bytes added , 10 December 2023

2,851

edits

@@ Line 377: / Line 377: @@
 |-
 |{{pmid text|36443648}}
+|[[RCT]], 24-week
+* placebo
+* 250 mg/day
 |
+* male patients with diabetes
+* reduced grip strength (<26 kg) or walking speed (<1.0 m/s)
+* age ≥ 65
 |
-|
+* NMN was tolerable without any severe adverse events
+* NMN did not improve grip strength and walking speed
+* Improved prevalence of frailty in the NMN group (P = 0.066)
+* Different changes in central retinal thickness between the two groups (P = 0.051)
 |-
 |{{pmid_text|37718359}}